Team:Virginia/Project Overview

From 2013.igem.org

(Difference between revisions)
 
(3 intermediate revisions not shown)
Line 236: Line 236:
                 <p><a href="https://2013.igem.org/Team:Virginia/Results">Results</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Results">Results</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Modeling">Modeling</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Modeling">Modeling</a></p>
-
                 <p><a href="https://2013.igem.org/Team:Virginia/Applications">Chassis Improvements</a></p></span>
+
                 <p><a href="https://2013.igem.org/Team:Virginia/Software">Software</a></p>
 +
 
 +
                <p><a href="https://2013.igem.org/Team:Virginia/Chassis_Improvements">Chassis Improvements</a></p></span>
         </li>
         </li>
         <li>
         <li>
Line 247: Line 249:
         </li>
         </li>
         <li>
         <li>
-
                <span class="title">Human Practices</span>
+
                          <span class="title">Human Practices</span>
                 <span class="text">
                 <span class="text">
                 <p><a href="https://2013.igem.org/Team:Virginia/Human_Practices_Overview">Overview</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Human_Practices_Overview">Overview</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Safety Considerations">Safety Considerations</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Safety Considerations">Safety Considerations</a></p>
-
                 <p><a href="https://2013.igem.org/Team:Virginia/Outreach">High School Education Series</a></p>
+
                 <p><a href="https://2013.igem.org/Team:Virginia/High_School_Education_Series">High School Education Series</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Documentary">Documentary</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Documentary">Documentary</a></p>
-
                 <p><a href="https://2013.igem.org/Team:Virginia/Relevance">Media Coverage</a></p></span>
+
                 <p><a href="https://2013.igem.org/Team:Virginia/Media_Coverage">Media Coverage</a></p>
 +
</span>
         </li>
         </li>
         <li>
         <li>
Line 268: Line 271:
<span><u>Project Overview</u></span>
<span><u>Project Overview</u></span>
<br><br>
<br><br>
-
<p><u> The Problem </u></p>
+
<p><u> Opportunity: Synthesizing a Better Drug Delivery Vector </u></p>
-
<p> <p style="text-indent: 5em;">There have always been public concerns over the safety of synthetic biology projects. Many of these concerns result from the possibility that bacteria may replicate or mutate beyond a scientist’s control. Efforts to increase the safety of bacterial chassis have thus far focused on engineering more reliable kill-switches or on reducing the expression of certain genes. We present bacterial minicells as a safe, alternative chassis that cannot proliferate (for lack of chromosomal DNA), but that still retain surface proteins from the parent cell and their ability to express plasmid DNA. </p>
+
<p> <p style="text-indent: 5em;">Every freely administered drug causes side effects. Cancer is a classic example. Because of off-target toxicity, many cancer patients have to hope that their chemotherapy kills their cancer before it kills them. </p>
 +
<p style="text-indent: 5em;"> Many drug delivery nano-vectors have been developed to address this issue. However, most have severely limiting disadvantages. For example, liposomes, the vector projected to have the largest market share in the next ten years, are often expensive to produce and leaky in functionality. </p>
 +
<p><p style="text-indent: 5em;">Bacteria have several properties that would make them an interesting alternative drug delivery vectors.
 +
<ul><li>Their surface membranes can be modified for targeting </li>
 +
<li>Biological and can accommodate Biobricks </li>
 +
<li>Easily grown and manufactured, unlike many other drug delivery vectors. </li>
 +
</ul></p>  
<br>
<br>
-
<p><u> An Alternative Solution </u></p>
+
<p style="text-indent: 5em;"> Unfortunately, as in the case of many potential synthetic biology applications, the utility of bacteria as vectors is limited by safety concerns. Our initial investigation on this problem led us to a forgotten discovery from the 1950’s—the bacterial minicell. </p>
-
<p><p style="text-indent: 5em;">Our initial investigation led us to a forgotten discovery from the 1950’s—the bacterial minicell. Minicells are small, achromosomal products of aberrant cell division. Because they lack chromosomes , they cannot replicate, mutate, or express virulent bacteria genes. However, they still express transfected plasmids, which means that minicells remain fully compatible with standardized biobrick parts.
+
<p style="text-indent: 5em;"> Minicells are small, achromosomal products of aberrant cell division. Because they lack chromosomes , they cannot replicate, mutate, or express virulent bacteria genes. However, they still express transfected plasmids, which means that minicells remain fully compatible with standardized biobrick parts. While largely neglected for decades, minicells are only now resurfacing, in the wake of the recent, explosive growth of the modern biotechnology industry. This past summer, we engineered the bacterial minicell into a safe, alternative chassis for drug delivery applications. </p>
-
While largely neglected for decades, minicells are only now resurfacing, in the wake of the recent, explosive growth of the modern biotechnology industry. The goals of our project were to increase iGEM access to minicells and to modify the surface membranes of minicells to further increase safety.  
+
-
</p>  
+
  </div></div></div>
  </div></div></div>

Latest revision as of 01:54, 29 October 2013

VGEM Welcomes You!

Project Overview

Opportunity: Synthesizing a Better Drug Delivery Vector

Every freely administered drug causes side effects. Cancer is a classic example. Because of off-target toxicity, many cancer patients have to hope that their chemotherapy kills their cancer before it kills them.

Many drug delivery nano-vectors have been developed to address this issue. However, most have severely limiting disadvantages. For example, liposomes, the vector projected to have the largest market share in the next ten years, are often expensive to produce and leaky in functionality.

Bacteria have several properties that would make them an interesting alternative drug delivery vectors.

  • Their surface membranes can be modified for targeting
  • Biological and can accommodate Biobricks
  • Easily grown and manufactured, unlike many other drug delivery vectors.


Unfortunately, as in the case of many potential synthetic biology applications, the utility of bacteria as vectors is limited by safety concerns. Our initial investigation on this problem led us to a forgotten discovery from the 1950’s—the bacterial minicell.

Minicells are small, achromosomal products of aberrant cell division. Because they lack chromosomes , they cannot replicate, mutate, or express virulent bacteria genes. However, they still express transfected plasmids, which means that minicells remain fully compatible with standardized biobrick parts. While largely neglected for decades, minicells are only now resurfacing, in the wake of the recent, explosive growth of the modern biotechnology industry. This past summer, we engineered the bacterial minicell into a safe, alternative chassis for drug delivery applications.